Capture hydrolysis signals in the microsomal stability assay: Molecular mechanisms of the alkyl ester drug and prodrug metabolism
Graphical abstract
Section snippets
Acknowledgments
The author thanks Pfizer’s high-throughput ADME screening group for historical HLM data generation; and Dr. Chris Keefer for programing and implementing a pairwise analysis tool on Pfizer’s computing platform.
References and notes (22)
- et al.
Bioorg. Med. Chem.
(2011) - et al.
Bioorg. Med. Chem. Lett.
(2009) - et al.
Biochem. Biophys. Res. Commun.
(2001) - et al.
- Drug Approvals and Databases, U.S. Food and Drug Administration,...
- et al.
J. Chem. Res. Toxicol.
(2000) - et al.
Chem. Res. Toxicol.
(2008) - Sun, H.; Keefer, C. E.; Scott, D. O. Drug Metabolism Letters 2011, 5, in...
- et al.
Nat. Struct. Biol.
(2003)
Chem. Biol. Drug Des.
(2010)
Cited by (11)
Structure-activity relationships of imidazole-derived 2-[ N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme
2015, European Journal of Medicinal ChemistryCovalent inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by the carbamates JZL184 and URB597
2012, Biochemical PharmacologyCitation Excerpt :Drugs and prodrugs that are esters of carboxylic acids are in general more lipophilic and better absorbed than the corresponding carboxylic acid [20], making them popular for clinical use. CES1 and CES2 are known to metabolize these ester drugs [20]. Thus, covalent interaction of pharmaceutical agents with CES1 and CES2 leading to enzyme inhibition may affect the metabolism and bioavailability of many ester drugs that are already in use.
Using Crystal Structures of Drug-Metabolizing Enzymes in Mechanism-Based Modeling for Drug Design
2020, Structural Biology in Drug Discovery: Methods, Techniques, and Practices
Copyright © 2011 Elsevier Ltd. All rights reserved.